» Articles » PMID: 8115781

Residual Tumor (R) Classification and Prognosis

Overview
Specialty Oncology
Date 1994 Jan 1
PMID 8115781
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor status following treatment is described by the residual tumor (R) classification: R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor. Residual tumor may be found in the area of primary tumor and its regional lymph nodes and/or at distant sites. The R classification reflects the effects of treatment and influences further treatment planning. Furthermore, the R classification is a strong predictor of prognosis. An acceptable long-term prognosis can be expected only in R0 patients. Although there exist clear correlations between stage and R classification the differences in prognosis of R0 versus R1,2 cannot be explained by differences in stage alone. The prognostic significance of R classification is demonstrated by respective data for non-small cell lung carcinoma, squamous cell carcinoma of oesophagus, gastric carcinoma, ductal adenocarcinoma of the pancreas, colorectal carcinoma, lung and liver metastases.

Citing Articles

Outcomes and Management of Positive Margins in Chondrosarcoma With Soft Tissue Extension: A Case Series and Review of Literature.

Yu A, Poulson T, Butler Z, Demetrious M, Gitelis S, Blank A Cancer Rep (Hoboken). 2025; 8(3):e70148.

PMID: 40067011 PMC: 11894820. DOI: 10.1002/cnr2.70148.


Evaluating the surgical and oncological outcomes of hepatic artery variations in minimally invasive pancreaticoduodenectomy: insights from 2023 data at a high-volume pancreatic center.

Li T, Dong L, Zhang D, Han J, Dai M, Guo J World J Surg Oncol. 2025; 23(1):44.

PMID: 39920789 PMC: 11804064. DOI: 10.1186/s12957-025-03704-6.


A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.

Zeng Q, Zhou Z, Zhang J, Cai R, Yang H, Chen P BMC Cancer. 2025; 25(1):112.

PMID: 39838301 PMC: 11752828. DOI: 10.1186/s12885-024-13390-4.


Updated Review of Proximal Gastrectomy for Gastric Cancer or Cancer of the Gastroesophageal Junction.

Irino T, Ohashi M, Hayami M, Makuuchi R, Ri M, Sano T J Gastric Cancer. 2025; 25(1):228-246.

PMID: 39822177 PMC: 11739649. DOI: 10.5230/jgc.2025.25.e12.


A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant....

Foroughi F, Javadinia S, Salek R Front Oncol. 2024; 14:1468279.

PMID: 39711967 PMC: 11660088. DOI: 10.3389/fonc.2024.1468279.